Hypertension and nephrology - 2017;21(06)

Hypertension and nephrology

DECEMBER 10, 2017

Hypertension and nephrology

DECEMBER 10, 2017

Hypertension and nephrology

DECEMBER 10, 2017

[Novelties in treatment of hypertension in pregnancy]

ALFÖLDI Sándor

[Hypertensive disorders represent the most common and dangerous medical disorder in pregnancy. Furthermore, its prevalence is rising. According the recent studies the initiation of antihypertensive treatment should be withhold in mild chronic hypertension (140-159/90-109 mmHg) in pregnancy, excepting associated subclinical hypertensive organ damage or hypertensive complications because of risk of compromising uteroplacental perfusion and fatal circulation. In preeclampsia, however, early antihypertensive treatment is necessary for the prevention of maternal cerebrovascular events.]

Hypertension and nephrology

DECEMBER 10, 2017

[From healthcare accross health affair to „whole-ness” affair ]

VÁLYI Péter

[The present healthcare system is mainly disease-centered. There is an increased need in a health model, that considerates the human being, his or her health, health status, their effects on every day life activities, on filling of his or her social tasks, takes into account the influential role of physical, social, economical factors and personal characteristics as well. A such of kind health model should be developed, that considerates the whole human being, the completness of his or her health affairs, and simultaneously is a part of a „whole-ness” affair-, human-centered system, taking into account physical, social, economical and political factors at the same time.]

Hypertension and nephrology

DECEMBER 10, 2017

[Strategies for increasing physical activity in chronic kidney insufficiency. Why to train in CKD?]

APOR Péter

[Chronic kidney patients are prone to lose their muscles, strength, their physical functioning and parallel to this the life expectancies are diminish. Physical training is a natural way to delaying these devastating processes in every grade of the illness. Centre-based or home, ambulant or dialysis-bound forms of programs are published – some of that recent information are summarized in this paper.]

Hypertension and nephrology

DECEMBER 10, 2017

[Gout, hyperuricaemia and cardiovascular risk - Effects of allopurinol]

KÉKES Ede

[Hyperuricemia has an increasing clinical relevance due to its pathomechanism and its presence and adverse effects on cardiovascular, metabolic and renal diseases today. Its presence is a world phenomenon and in our country, we have seen increasing incidence rates during the screening surveys in recent years. Convincing evidence suggests that the high uric acid values in cardiovascular and renal diseases is an independent risk factor for CV mortality and their clinical manifestations. Experimental and clinical evidences indicates that in addition to gout, all high uric acid levels should be considered to initiate the XO inhibitor allopurinol treatment. Recently, in some diseases, in the treatment of the underlying disease (especially elderly hypertension, ischemic heart disease, chronic heart failure, chronic kidney failure) is also considered as an adjunct therapy.]

Hypertension and nephrology

DECEMBER 10, 2017

[Place of rilmenidine therapy in reducing of sympathetic overactivity]

FINTA Ervin, KUN Edit, SIMONYI Gábor

[The sympathetic nervous system plays an important and widely investigated role in the pathogenesis of the hypertension and its concomitant diseases. Between the several types of antihypertensive drugs which can influence the sympathetic over activity, centrally acting agents, play an important role. Here some special aspects of the imidazoline I1 receptor agonist rilmenidine are reviewed.]

Hypertension and nephrology

DECEMBER 10, 2017